Abstract 4308: 3D nuclear telomeric signatures define circulating tumor cells (CTCs) and characterize CTC subpopulations in intermediate risk prostate cancer patients

Intermediate risk prostate cancer is a current medical challenge since the patients in this group can either be stable or progress, and there is no predictor for individual risk. Stratifying these patients would spare the patients unnecessary treatment or indicate the start of treatment immediately without losing precious time. Currently, prostate specific antigen (PSA) is used as evidence for biochemical progression. A more sensitive biomarker...